Search Result

Isoforms Recommended:	PDE10

Results for "

PDE10

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Endogenous Metabolite (4) iGluR (1) Isotope-Labeled Compounds (1) NO Synthase (4) Phosphodiesterase (PDE) (40) PKA (3) Small Interfering RNA (siRNA) (3)
By Research Areas:	Cancer (3) Cardiovascular Disease (9) Endocrinology (4) Inflammation/Immunology (1) Metabolic Disease (5) Neurological Disease (24)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12813

PDE10-IN-1	Phosphodiesterase (PDE)	Neurological Disease
PDE10-IN-1 is a potent PDE10-IN-1 inhibitor extracted from Patent WO 2013192273 A1, for treating CNS and metabolic disorders.

HY-14550A

PDE10-IN-5	Phosphodiesterase (PDE)	Others
PDE10-IN-5 is a phosphodiesterase 10 (PDE 10) inhibitor, can be used for researching certain central nervous system (CNS) disorders .

HY-131973

PDE10A-IN-2 hydrochloride	Phosphodiesterase (PDE)	Cardiovascular Disease Metabolic Disease
PDE10A-IN-2 hydrochloride is a potent, highly selective and orally active phosphodiesterase 10A (PDE10A) inhibitor with an IC₅₀ of 2.8 nM. PDE10A-IN-2 hydrochloride shows selectivity of >3500-fold against other PDE subtypes. PDE10A-IN-2 hydrochloride can be used for pulmonary arterial hypertension (PAH) research .

HY-12813A

PDE10-IN-2	Phosphodiesterase (PDE)	Neurological Disease
PDE10-IN-2 is a *PDE10* inhibitor with an IC₅₀≦0.01 μM .

HY-120684

PDE10-IN-6	Phosphodiesterase (PDE)	Others
PDE10-IN-6 is a phosphodiesterase-10 inhibitor that inhibits the breakdown of cAMP and cGMP, thereby slowing or halting their hydrolysis.

HY-158237

PDE10A-IN-3	Phosphodiesterase (PDE)	Neurological Disease
PDE10A-IN-3 (Compound 8a) is an inhibitor of phosphodiesterase 10A (PDE10A). PDE10A-IN-3 can be used in schizophrenia research .

HY-123154

PDE10A-IN-4	Phosphodiesterase (PDE)	Others
PDE10A-IN-4 (compound 38) is a compound used to inhibit schizophrenia. As a PDE10A inhibitor, it is less effective than placebo in inhibiting acute schizophrenia and does not show antipsychotic effect.

HY-RS10201

Pde10a Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Pde10a Rat Pre-designed siRNA Set A contains three designed siRNAs for Pde10a gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pde10a Rat Pre-designed siRNA Set A Pde10a Rat Pre-designed siRNA Set A

HY-RS10199

PDE10A Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
PDE10A Human Pre-designed siRNA Set A contains three designed siRNAs for PDE10A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PDE10A Human Pre-designed siRNA Set A PDE10A Human Pre-designed siRNA Set A

HY-RS10200

Pde10a Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Pde10a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pde10a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pde10a Mouse Pre-designed siRNA Set A Pde10a Mouse Pre-designed siRNA Set A

HY-U00427

PDE2/PDE10-IN-1	Phosphodiesterase (PDE)	Neurological Disease
PDE2/PDE10-IN-1 is a phosphodiesterase 2 (PDE2) and *PDE10* inhibitor with IC₅₀s of 29 and 480 nM, respectively.

HY-100530B

Sp-cAMPS	PKA Phosphodiesterase (PDE)	Neurological Disease Metabolic Disease
Sp-cAMPS, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a K_i of 47.6 µM. Sp-cAMPS binds the PDE10 GAF domain with an EC₅₀ of 40 μM .

HY-100530C

Sp-cAMPS sodium salt	PKA Phosphodiesterase (PDE)	Neurological Disease Metabolic Disease
Sp-cAMPS sodium salt, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS sodium salt is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a K_i of 47.6 µM. Sp-cAMPS sodium salt binds the PDE10 GAF domain with an EC₅₀ of 40 μM .

HY-110005

Sp-cAMPS triethylamine	PKA Phosphodiesterase (PDE)	Neurological Disease Metabolic Disease
Sp-cAMPS triethylamine, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS triethylamine is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a K_i of 47.6 µM. Sp-cAMPS triethylamine binds the PDE10 GAF domain with an EC₅₀ of 40 μM .

HY-170435

PDE5-IN-13	Phosphodiesterase (PDE)	Cardiovascular Disease
PDE5-IN-13 (Compound 14b) inhibits phosphodiesterase 5 (PDE5A) with an IC₅₀ of 3 nM. PDE5-IN-13 is a potential candidate for PAH (pulmonary arterial hypertension) research. PDE5-IN-13 has high selectivity for targets over PDE1, PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11. PDE5-IN-13 is orally active .

HY-18252

Avanafil 1 Publications Verification TA1790	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite	Cardiovascular Disease Endocrinology
Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-18252R

Avanafil (Standard)	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite	Cardiovascular Disease Endocrinology
Avanafil (Standard) is the analytical standard of Avanafil. This product is intended for research and analytical applications. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-18252A

Avanafil dibenzenesulfonate TA1790 dibenzenesulfonate	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite	Cardiovascular Disease Endocrinology
Avanafil (TA-1790) dibenzenesulfonate is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil dibenzenesulfonate activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil dibenzenesulfonate inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil dibenzenesulfonate can be used for the research of erectile dysfunction and osteoporosis .

HY-113972R

Methyl mycophenolate (Standard)	Others	Inflammation/Immunology
Avanafil (Standard) is the analytical standard of Avanafil. This product is intended for research and analytical applications. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-18252S1

Avanafil-13C5,15N,d2	Endogenous Metabolite NO Synthase Phosphodiesterase (PDE) Isotope-Labeled Compounds	Cardiovascular Disease Endocrinology
Avanafil- ¹³C₅, ¹⁵N,d₂ is ¹⁵N and deuterated labeled Avanafil (HY-18252). Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-128349

MT-3014	Phosphodiesterase (PDE)	Neurological Disease
MT-3014 is a potent, highly selective and brain-penetrated phosphodiesterase 10A (PDE 10A) inhibitor, with IC₅₀s of 0.062 nM and 0.09 nM for human PDE 10A and bovine PDE 10A, respectively .

HY-124392

AMG580	Phosphodiesterase (PDE)	Cancer
AMG580 is a selective *PDE10A* antagonist with subnanomolar affinity for rat, primate, and human PDE10A. AMG580 can be used for the research of noninvasive radiotracer .

HY-123743

JNJ-42314415	Phosphodiesterase (PDE)	Neurological Disease
JNJ-42314415 is a centrally active phosphodiesterase 10A (PDE10A) inhibitor, with K_i values of 35 nM and 64 nM for human recombinant PDE10A and rPDE10A, respectively .

HY-18037

AMG-7980	Phosphodiesterase (PDE)	Others
AMG-7980 exhibits high affinity to phosphodiesterase 10A (PDE10A), with a K_D of 0.94 nM. AMG-7980 can be used as a tracer of PDE10A, when labeled with radioactive isotope .

HY-117604

THPP-1	Phosphodiesterase (PDE)	Neurological Disease
THPP-1, a SGC chemical probe, is a potent and orally bioavailable phosphodiesterase 10A (PDE10A) inhibitor, with K_i values of 1 nM and 1.3 nM for human and rat PDE10A, respectively. THPP-1 has excellent pharmacokinetic properties in preclinical species .

HY-12913

AMG 579	Phosphodiesterase (PDE)	Neurological Disease
AMG 579 is a potent, selective, and efficacious inhibitor of phosphodiesterase 10A (PDE10A) with an IC₅₀ of 0.1 nM.

HY-10568

TC-E 5005	Phosphodiesterase (PDE)	Metabolic Disease
TC-E 5005 is a potent and selective *PDE10A* inhibitor with IC₅₀ values of 7.28, 239, 779, 919, 3,100, and 3,700 nM for PDE10A, 2A, 11A, 5A, 7B and 3A, respectively. TC-E 5005 inhibits adrenergic and neurogenic smooth muscle contractions in the human prostate .

HY-152838

Gemlapodect RO554965	Phosphodiesterase (PDE)	Neurological Disease
Gemlapodect (RO554965) is an inhibitor of phosphodiesterase 10A (PDE10A). Gemlapodect can be used for researching schizophrenia .

HY-160111

PDM-042	Phosphodiesterase (PDE)	Neurological Disease
PDM-042 is a potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor. PDM-042 shows potent inhibitory activities for human and rat PDE10A with IC₅₀ values of less than 1 nM and more than 1000-fold selectivity against other phosphodiesterases. PDM-042 can be used for the research of schizophrenia .

HY-135848

N-Methylbenzamide	Phosphodiesterase (PDE)	Cancer
N-Methylbenzamide is a potent phosphodiesterase 10A (PDE10A) inhibitor. N-Methylbenzamide has anti-cancer activity .

HY-153093

MK-8189	Phosphodiesterase (PDE)	Neurological Disease
MK-8189 is a potent, orally active and selective *PDE10A* inhibitor with a K_i value of 29 pM. MK-8189 can be used in research of schizophrenia .

HY-12472

Balipodect 2 Publications Verification TAK-063	Phosphodiesterase (PDE)	Neurological Disease
Balipodect (TAK-063) is a highly potent, selective and orally active PDE10A inhibitor with IC₅₀ of 0.30 nM; >15000-fold selectivity over other PDEs.

HY-117838

Phosphodiesterase 10-IN-2	Phosphodiesterase (PDE)	Neurological Disease
Phosphodiesterase 10-IN-2 (THPP-4) is an oral active phosphodiesterase 10A (PDE10A) inhibitor with the K_i of 4.5 nM. Phosphodiesterase 10-IN-2 can be used for study of schizophrenia .

HY-123446

JNJ-42259152	Phosphodiesterase (PDE)	Neurological Disease
JNJ-42259152 is a phosphodiesterase 10A (PDE10A) positron emission tomography (PET) tracer that is specific for PDE10A activity. JNJ-42259152 can be dynamically scanned in healthy volunteers to assess its kinetic properties in the brain. The half-life of JNJ-42259152 in the blood is an average of 90 minutes. JNJ-42259152 has demonstrated reliable binding potential (BPND) in different target areas (such as the lentiform nucleus, caudate nucleus, ventral striatum, etc.), providing an important tool for studying neuropsychiatric diseases .

HY-50098

Mardepodect 2 Publications Verification PF-2545920	Phosphodiesterase (PDE)	Neurological Disease
Mardepodect (PF-2545920) is a potent, orally active and selective *PDE10A* inhibitor with an IC₅₀ of 0.37 nM, with >1000-fold selectivity over other *PDEs*. Mardepodect can cross the blood-brain barrier .

HY-50098A

Mardepodect hydrochloride 2 Publications Verification PF-2545920 hydrochloride	Phosphodiesterase (PDE)	Cancer
Mardepodect hydrochloride (PF-2545920 hydrochloride) is a potent, orally active and selective *PDE10A* inhibitor with an IC₅₀ of 0.37 nM, with >1000-fold selectivity over other *PDEs*. Mardepodect hydrochloride can cross the blood-brain barrier .

HY-10030

Mardepodect succinate PF-2545920 succinate	Phosphodiesterase (PDE)	Neurological Disease
Mardepodect succinate (PF-2545920 succinate) is a potent and specific phosphodiesterase 10A (PDE10A) inhibitor with potential activity in the treatment of schizophrenia. Mardepodect succinate has been further optimized to improve brain penetration and compound-like properties for use in schizophrenia research .

HY-W003486

5,7-Dichloropyrazolo[1,5-a]pyrimidine	Phosphodiesterase (PDE)	Neurological Disease
5,7-Dichloropyrazolo[1,5-a]pyrimidine (fragment 5) is a pyrazolopyrimidine phosphodiesterase 10A (PDE10A) inhibitor (K_i=24 μM). 5,7-Dichloropyrazolo[1,5-a]pyrimidine can be used in the study of schizophrenia .

HY-14550

TP-10 1 Publications Verification	Phosphodiesterase (PDE)	Cardiovascular Disease Neurological Disease
TP-10 is a selective *PDE10A* inhibitor with an IC₅₀ value of 0.8 nM. TP-10 shows an antioxidant activity with IC₅₀s of 31.72 and 16.04 μg/ml for DPPH and CUPRAC, respectively. TP-10 can be used for the research of neuropathy .

HY-18078

PQ-10	Phosphodiesterase (PDE)	Neurological Disease
PQ-10 is a potent inhibitor of Phosphodiesterase 10A (PDE10A) with IC₅₀ andED₅₀ of 4.6 nM and 13 mg/kg, respectively. PQ-10 induces patterns of brain glucose metabolism which can be a potential translational biomarker. PQ-10 has the potential for researching psychiatric disorders like schizophrenia .

HY-112704

PDE5-IN-2	Phosphodiesterase (PDE)	Cardiovascular Disease
PDE5-IN-2 is a potent, highly selective, and orally active *PDE5* inhibitor, with an IC₅₀ of 0.31 nM, less potently inhibits PDE2A, PDE10A, PDE4D2, and PDE6C, with IC₅₀s of 106, 46, 43, 1.2 nM, respectively. Anti-pulmonary arterial hypertension activity .

HY-161663

Phosphodiesterase-IN-2	Phosphodiesterase (PDE)	Cardiovascular Disease
Phosphodiesterase-IN-2 (Compound C7) is a selective, orally active inhibitor for phosphodiesterase 10A (PDE10A), with an IC₅₀ of 11.9 nM. Phosphodiesterase-IN-2 improves the stability of liver microsomes, and lowers BBB permeability. Phosphodiesterase-IN-2 exhibits good pharmacokinetic characters, and attenuates isoprenaline (HY-108353)-induced cardiac hypertrophic in mouse models .

HY-112831

Osoresnontrine 1 Publications Verification BI-409306	Phosphodiesterase (PDE)	Neurological Disease
Osoresnontrine (BI-409306) is a potent and selective *PDE9A* inhibitor, with an IC₅₀ of 52 nM, and shows weak activity against other PDEs, such as PDE1A (IC₅₀, 1.4 µM), PDE1C (IC₅₀, 1.0 µM), PDE2A, PDE3A, PDE4B, PDE5A, PDE6AB, PDE7A, and PDE10A (IC₅₀ all > 10 μM); Osoresnontrine can be used in the research of memory enhancement in CNS disorders.

HY-168966

PDE2 inhibitor 6	Phosphodiesterase (PDE) iGluR	Neurological Disease
PDE2 inhibitor 6 (Compound 1) is the orally active inhibitor for phosphodiesterase (PDE) that inhibits *PDE2A, PDE3B, and PDE10A2* with IC₅₀s of 0.95 nM, 6.17 μM (pIC₅₀=5.21) and 87.1 nM (pIC₅₀=7.06), respectively. PDE2 inhibitor 6 modulates the activity of AMPA receptor, enhance the synaptic plasticity and promotes the learning and memory function in rats models. PDE2 inhibitor 6 can cross blood-brain barrier .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-18252

Avanafil 1 Publications Verification TA1790	Cardiovascular Disease Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Endocrinology	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite
Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-18252R

Avanafil (Standard)	Structural Classification Natural Products Source classification Endogenous metabolite	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite
Avanafil (Standard) is the analytical standard of Avanafil. This product is intended for research and analytical applications. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-18252A

Avanafil dibenzenesulfonate TA1790 dibenzenesulfonate	Cardiovascular Disease Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Endocrinology	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite
Avanafil (TA-1790) dibenzenesulfonate is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil dibenzenesulfonate activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil dibenzenesulfonate inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil dibenzenesulfonate can be used for the research of erectile dysfunction and osteoporosis .

HY-113972R

Methyl mycophenolate (Standard)	Structural Classification Monophenols Microorganisms Marine natural products Phenols Marine microorganism	Others
Avanafil (Standard) is the analytical standard of Avanafil. This product is intended for research and analytical applications. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

Cat. No.	Product Name	Chemical Structure

HY-18252S1

Avanafil-13C5,15N,d2

Avanafil- ¹³C₅, ¹⁵N,d₂ is ¹⁵N and deuterated labeled Avanafil (HY-18252). Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

PDE10

Inhibitors & Agonists

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products